<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343368</url>
  </required_header>
  <id_info>
    <org_study_id>2010LS053</org_study_id>
    <secondary_id>012M93555</secondary_id>
    <nct_id>NCT01343368</nct_id>
  </id_info>
  <brief_title>Preservation of Ovarian Function After Hematopoietic Cell Transplant</brief_title>
  <official_title>A Phase II Trial of GnRH Agonist for the Preservation of Ovarian Function After Hematopoietic Cell Transplantation (HCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Minnesota Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive
      GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be
      observed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to use gonadotropin releasing hormone (GnRH) agonist leuprolide prior
      myeloablative hematopoietic cell transplantation to prevent ovarian dysfunction in
      post-menarchal women.

      The primary objective is to determine the effect of GnRH agonists on the incidence of ovarian
      failure.

      The secondary objectives are

        -  to determine how effective GnRH agonists are at suppressing menses during

        -  to determine the incidence and timing of resumption of menstrual cycles after HCT

        -  to determine the incidence and timing of resumption of normal FSH and LH levels after
           HCT

        -  to determine the incidence of normal AMH levels after HCT

        -  to determine the effect of GnRH agonists on immune reconstitution after HCT

        -  to assess the safety and tolerability of GnRH agonists in the context of HCT

      A total of 47 patients will be accrued in this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Number of Patients With Ovarian Failure</measure>
    <time_frame>Through Day 180 Post Transplant</time_frame>
    <description>Comparison of treatment arms; interventional versus observational. Ovarian failure rate is based on FSH measured at 180 days after HCT; to determine the effect of GnRH agonists on the incidence of ovarian failure (i.e. FSH &gt;40 IU/L) after transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Number of Patients Who Stopped Menstrual Bleeding</measure>
    <time_frame>From Baseline Through Day 365</time_frame>
    <description>Comparison of treatment arms; interventional versus observational. Count of patients who stopped menstrual bleeding; to determine how the effect of GnRH agonists are at suppressing menses during hematopoietic cell transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Follicle Stimulating Hormone (FSH) Levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Follicle Stimulating Hormone (FSH) Levels</measure>
    <time_frame>Day 100</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Follicle Stimulating Hormone (FSH) Levels</measure>
    <time_frame>Day 180</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Follicle Stimulating Hormone (FSH) Levels</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Follicle Stimulating Hormone (FSH) Levels</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Number of Patients Who Resumed Menstrual Cycles</measure>
    <time_frame>Day 365 Post Transplant</time_frame>
    <description>Comparison of treatment arms; interventional versus observational. Count of patients who resumed menses after hematopoietic cell transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Lutineizing Hormone (LH) Levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Luteinizing Hormone (LH) Levels</measure>
    <time_frame>Day 100</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Luteinizing Hormone (LH) Levels</measure>
    <time_frame>Day 180</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Luteinizing Hormone (LH) Levels</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Leuprolide Hormone (LH) Levels</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antimullerian Hormone (AMH) Levels After Transplant</measure>
    <time_frame>Day Prior to Transplant</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average AMH levels after receiving transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Antimullerian Hormone (AMH) Levels After Transplant</measure>
    <time_frame>Day 180 after Transplant</time_frame>
    <description>Comparison of treatment arms; interventional versus observational average AMH levels after receiving transplant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myeloproliferative Disorders</condition>
  <arm_group>
    <arm_group_label>Interventional - Received Leuprolide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days</description>
    <arm_group_label>Interventional - Received Leuprolide</arm_group_label>
    <other_name>Lupron Depot-3(R)</other_name>
    <other_name>Leuprolide acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hematopoietic cell transplant</intervention_name>
    <description>Conventional bone marrow transplant regimen.</description>
    <arm_group_label>Interventional - Received Leuprolide</arm_group_label>
    <other_name>HCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>reduced intensity allogeneic HCT</intervention_name>
    <description>A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
    <arm_group_label>Observational Arm</arm_group_label>
    <other_name>RIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Interventional Arm:

               -  Eligible for myeloablative allogenic or autologous hematopoietic cell transplant
                  (HCT)

               -  Post-menarchal female &lt; or = 50 years of age

               -  Normal antimullerian hormone (AMH) level and/or follicle stimulating hormone
                  (FSH)/leuprolide (LH) levels for age/stage of puberty

               -  Those women who have an FSH &gt; 40 IU/L and whose diagnosis of malignancy and whose
                  chemotherapy treatment was within 12 weeks of enrollment are still eligible if
                  they had normal menstrual cycles pre-diagnosis.

          -  Observational Arm:

               -  Eligible for reduced intensity allogeneic HCT

               -  Post-menarchal female â‰¤ 50 years of age

               -  Normal AMH level and/or FSH/LH for age/stage of puberty

               -  Those women who an FSH &gt;40 IU/L and whose diagnosis of malignancy and
                  chemotherapy treatment was within 12 weeks of enrollment are still eligible if
                  they had normal menstrual cycles pre-diagnosis.

        Exclusion Criteria:

          -  All Arms:

               -  History of ovarian cancer

               -  Surgical resection of one or both ovaries. Prior hysterectomy is allowed as long
                  as the ovaries are intact.

               -  Use of GnRH agonist in last 12 months will exclude patients if lab results are
                  not available to demonstrate adequate ovarian function prior to initiation of
                  GnRH therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Smith, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <results_first_submitted>June 19, 2017</results_first_submitted>
  <results_first_submitted_qc>June 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2017</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-menarchal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Interventional - Received Leuprolide</title>
          <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
        </group>
        <group group_id="P2">
          <title>Observational Arm</title>
          <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Interventional - Received Leuprolide</title>
          <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
        </group>
        <group group_id="B2">
          <title>Observational Arm</title>
          <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Number of Patients With Ovarian Failure</title>
        <description>Comparison of treatment arms; interventional versus observational. Ovarian failure rate is based on FSH measured at 180 days after HCT; to determine the effect of GnRH agonists on the incidence of ovarian failure (i.e. FSH &gt;40 IU/L) after transplant.</description>
        <time_frame>Through Day 180 Post Transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Number of Patients With Ovarian Failure</title>
          <description>Comparison of treatment arms; interventional versus observational. Ovarian failure rate is based on FSH measured at 180 days after HCT; to determine the effect of GnRH agonists on the incidence of ovarian failure (i.e. FSH &gt;40 IU/L) after transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Number of Patients Who Stopped Menstrual Bleeding</title>
        <description>Comparison of treatment arms; interventional versus observational. Count of patients who stopped menstrual bleeding; to determine how the effect of GnRH agonists are at suppressing menses during hematopoietic cell transplant</description>
        <time_frame>From Baseline Through Day 365</time_frame>
        <population>Five patients on the Interventional arm and 10 patients on the Observational arm were lost to follow-up by Day 365.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Number of Patients Who Stopped Menstrual Bleeding</title>
          <description>Comparison of treatment arms; interventional versus observational. Count of patients who stopped menstrual bleeding; to determine how the effect of GnRH agonists are at suppressing menses during hematopoietic cell transplant</description>
          <population>Five patients on the Interventional arm and 10 patients on the Observational arm were lost to follow-up by Day 365.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Follicle Stimulating Hormone (FSH) Levels</title>
        <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
        <time_frame>Baseline</time_frame>
        <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Follicle Stimulating Hormone (FSH) Levels</title>
          <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
          <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="8.0"/>
                    <measurement group_id="O2" value="4.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Follicle Stimulating Hormone (FSH) Levels</title>
        <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
        <time_frame>Day 100</time_frame>
        <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis. One patient on the Interventional arm and 7 on the Observational arm were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Follicle Stimulating Hormone (FSH) Levels</title>
          <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
          <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis. One patient on the Interventional arm and 7 on the Observational arm were lost to follow-up.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="19.5"/>
                    <measurement group_id="O2" value="9.1" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Follicle Stimulating Hormone (FSH) Levels</title>
        <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
        <time_frame>Day 180</time_frame>
        <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis. One patient on the Interventional arm and 7 on the Observational arm were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Follicle Stimulating Hormone (FSH) Levels</title>
          <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
          <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis. One patient on the Interventional arm and 7 on the Observational arm were lost to follow-up.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0" spread="40.1"/>
                    <measurement group_id="O2" value="4.7" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Follicle Stimulating Hormone (FSH) Levels</title>
        <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
        <time_frame>1 year</time_frame>
        <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis. Three patients on the Interventional arm and 8 patients on the Observational arm were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Follicle Stimulating Hormone (FSH) Levels</title>
          <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
          <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis. Three patients on the Interventional arm and 8 patients on the Observational arm were lost to follow-up.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="97.6"/>
                    <measurement group_id="O2" value="48.8" spread="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Follicle Stimulating Hormone (FSH) Levels</title>
        <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
        <time_frame>2 years</time_frame>
        <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis. All 7 patients on the Interventional arm and 8 patients on the Observational arm were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Follicle Stimulating Hormone (FSH) Levels</title>
          <description>Comparison of treatment arms; interventional versus observational average FSH levels.</description>
          <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis. All 7 patients on the Interventional arm and 8 patients on the Observational arm were lost to follow-up.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7.1" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Number of Patients Who Resumed Menstrual Cycles</title>
        <description>Comparison of treatment arms; interventional versus observational. Count of patients who resumed menses after hematopoietic cell transplant</description>
        <time_frame>Day 365 Post Transplant</time_frame>
        <population>Only 6 of the 10 patients that started on the Observational Arm were evaluable. The 2 patients were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Number of Patients Who Resumed Menstrual Cycles</title>
          <description>Comparison of treatment arms; interventional versus observational. Count of patients who resumed menses after hematopoietic cell transplant</description>
          <population>Only 6 of the 10 patients that started on the Observational Arm were evaluable. The 2 patients were lost to follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Lutineizing Hormone (LH) Levels</title>
        <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
        <time_frame>Baseline</time_frame>
        <population>Four patients on the Observational arm never had any follow-up LH levels drawn and were removed from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Lutineizing Hormone (LH) Levels</title>
          <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
          <population>Four patients on the Observational arm never had any follow-up LH levels drawn and were removed from this analysis.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="30.2"/>
                    <measurement group_id="O2" value="6.8" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Luteinizing Hormone (LH) Levels</title>
        <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
        <time_frame>Day 100</time_frame>
        <population>Four patients on the Observational arm never had any follow-up LH levels drawn and were removed from this analysis. One patient on the Interventional arm and 7 on the Observational arm were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Luteinizing Hormone (LH) Levels</title>
          <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
          <population>Four patients on the Observational arm never had any follow-up LH levels drawn and were removed from this analysis. One patient on the Interventional arm and 7 on the Observational arm were lost to follow-up.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.7"/>
                    <measurement group_id="O2" value="6.4" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Luteinizing Hormone (LH) Levels</title>
        <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
        <time_frame>Day 180</time_frame>
        <population>Four patients on the Observational arm never had any follow-up LH levels drawn and were removed from this analysis. One patient on the Interventional arm and 7 on the Observational arm were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Luteinizing Hormone (LH) Levels</title>
          <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
          <population>Four patients on the Observational arm never had any follow-up LH levels drawn and were removed from this analysis. One patient on the Interventional arm and 7 on the Observational arm were lost to follow-up.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="32.0"/>
                    <measurement group_id="O2" value="4.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Luteinizing Hormone (LH) Levels</title>
        <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
        <time_frame>1 year</time_frame>
        <population>Four patients on the Observational arm never had any follow-up LH levels drawn and were removed from this analysis. Three patients on the Interventional arm and 8 patients on the Observational arm were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Luteinizing Hormone (LH) Levels</title>
          <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
          <population>Four patients on the Observational arm never had any follow-up LH levels drawn and were removed from this analysis. Three patients on the Interventional arm and 8 patients on the Observational arm were lost to follow-up.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="36.1"/>
                    <measurement group_id="O2" value="27.8" spread="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Leuprolide Hormone (LH) Levels</title>
        <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
        <time_frame>2 years</time_frame>
        <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis. All 7 patients on the Interventional arm and 8 patients on the Observational arm were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Leuprolide Hormone (LH) Levels</title>
          <description>Comparison of treatment arms; interventional versus observational average LH levels during study.</description>
          <population>Four patients on the Observational arm never had any follow-up FSH levels drawn and were removed from this analysis. All 7 patients on the Interventional arm and 8 patients on the Observational arm were lost to follow-up.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antimullerian Hormone (AMH) Levels After Transplant</title>
        <description>Comparison of treatment arms; interventional versus observational average AMH levels after receiving transplant.</description>
        <time_frame>Day Prior to Transplant</time_frame>
        <population>Six patients on the Observational arm never had any follow-up AMH levels drawn and were removed from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antimullerian Hormone (AMH) Levels After Transplant</title>
          <description>Comparison of treatment arms; interventional versus observational average AMH levels after receiving transplant.</description>
          <population>Six patients on the Observational arm never had any follow-up AMH levels drawn and were removed from this analysis.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.9"/>
                    <measurement group_id="O2" value="6.4" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Antimullerian Hormone (AMH) Levels After Transplant</title>
        <description>Comparison of treatment arms; interventional versus observational average AMH levels after receiving transplant.</description>
        <time_frame>Day 180 after Transplant</time_frame>
        <population>Four patients on the Observational and 10 patients on the Observational arm never had any follow-up AMH levels drawn and were removed from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Interventional - Received Leuprolide</title>
            <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
          </group>
          <group group_id="O2">
            <title>Observational Arm</title>
            <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antimullerian Hormone (AMH) Levels After Transplant</title>
          <description>Comparison of treatment arms; interventional versus observational average AMH levels after receiving transplant.</description>
          <population>Four patients on the Observational and 10 patients on the Observational arm never had any follow-up AMH levels drawn and were removed from this analysis.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Interventional - Received Leuprolide</title>
          <description>Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
Leuprolide: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
hematopoietic cell transplant: Conventional bone marrow transplant regimen.</description>
        </group>
        <group group_id="E2">
          <title>Observational Arm</title>
          <description>Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
reduced intensity allogeneic HCT: A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Liability</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Angela Smith</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-626-8094</phone>
      <email>smith719@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

